Search Results
Your search for all items matches 34730 pages
Showing 22501 - 22550Susan J. Mandel, MD, MPH, Named President-Elect of the Endocrine Society
Susan J. Mandel, MD, MPH, Director of Clinical Endocrinology and Diabetes for the University of Pennsylvania Health System, and Professor in the Division of Diabetes, Endocrinology, and Metabolism in Penn’s Perelman School of Medicine, has been elected President-Elect of the Endocrine Society. Dr. ...
Anne Gross, PhD, RN, NEA-BC, FAAN, Named Senior Vice President of Patient Care Services and Chief Nursing Officer at Dana-Farber
Anne Gross, PhD, RN, NEA-BC, FAAN, has been named Senior Vice President for Patient Care Services and Chief Nursing Officer at Dana-Farber Cancer Institute, effective December 1, 2016. Dr. Gross joined Dana-Farber in 2002 after 12 years at Cambridge Health Alliance as the nursing leader in...
A Lung Cancer Specialist Talks About Value in Cancer Care
Over the past few years, the term value-based cancer care has become integrated into the vernacular of the oncology community. Value is a subjective term, which is defined largely by its clinical setting. However, value in cancer care is evaluated by the multiple stakeholders involved in the...
Cary A. Presant, MD, FACP, FASCO, Receives ACCC David King Community Clinical Scientist Award
The Association of Community Cancer Centers (ACCC) honored Cary A. Presant, MD, FACP, FASCO, with the prestigious David King Community Clinical Scientist Award, for his demonstrated leadership in the development, participation, and evaluation of clinical studies for cancer patients. Throughout his ...
AMA Adopts Ethical Guidance on Team-Based Health Care
Team-based health-care models are emerging as preferred methods for providing coordinated, cost-effective and high-quality health care for patients. Earlier this month, the American Medical Association (AMA) announced its adoption of ethical guidance for physicians as leader-members of care ...
How Video Support Tools Help Patients Make Informed Decisions About End-of-Life Care
A relatively recent study by Areej El-Jawahri, MD, and her colleagues is showing how the use of visual media can empower patients with advanced cancer, as well as other life-threatening illnesses, to make more informed decisions about their end-of-life care.1 The aim of Dr. El-Jawahri’s study was ...
Understanding Biosimilars and Their Impending Role in Oncology Care
Biosimilars are among the newest threads in the fabric of cancer treatment in the United States, and they are spawning numerous questions for oncologists and patients with cancer. Many of these questions were taken up by participants in a recent Washington forum on “The Future of the U.S....
Charles G. Drake, MD, PhD, Joins NewYork-Presbyterian/Columbia University Medical Center
Charles G. Drake, MD, PhD, has joined NewYork-Presbyterian/Columbia University Medical Center as Director of Genitourinary Oncology and Associate Director for Clinical Research at the Herbert Irving Comprehensive Cancer Center. Dr. Drake will also serve as Co-Director of Columbia’s Cancer...
Adjuvant Sunitinib for Renal Cell Carcinoma: Not Ready for Prime Time
In renal cell carcinoma and other cancer types, a consistent paradigm in drug development exists: Observe efficacy of a drug in the metastatic setting and move quickly to explore the agent in the adjuvant setting. In the cytokine era, there were multiple efforts to characterize whether adjuvant...
Adjuvant Sunitinib Improves Disease-Free Survival in High-Risk Renal Cell Carcinoma After Nephrectomy
In the phase III S-TRAC trial reported at the recent European Society for Medical Oncology meeting and in The New England Journal of Medicine by Alain Ravaud, MD, PhD, of Bordeaux University Hospital, and colleagues, adjuvant sunitinib (Sutent) significantly prolonged disease-free survival vs...
Pembrolizumab in First-Line Treatment of Metastatic Non–Small Cell Lung Cancer
On October 24, 2016, pembrolizumab (Keytruda) was approved for use in patients with metastatic non–small cell lung cancer (NSCLC) whose tumors have high programmed cell death ligand 1 (PD-L1) expression (tumor proportion score ≥ 50%) as determined by a U.S. Food and Drug Administration...
At ESMO 2016, Many Phase III Trials Fail to Meet Primary Endpoints
The 2016 European Society for Medical Oncology (ESMO) Congress revealed many important positive findings from key trials in a number of tumor types, but many highly anticipated phase III trials in advanced disease failed to meet their primary endpoints. The ASCO Post has summarized several of these ...
Study Finds EXITS Gene Mutations May Contribute to Cancer Sex Bias
According to Surveillance, Epidemiology, and end Results (SEER) data from 2008 to 2012, American males have an excess risk of 20.4% of developing any cancer compared with females, and there is a ≥ 2:1 male predominance for some individual cancers. This excess risk results in approximately...
Expert Point of View: Laurence Albiges, MD, PhD
Formal discussant Laurence Albiges, MD, PhD, of Institut Gustave Roussy, Villejuif, France, tried to put the results of KEYNOTE-052 and CheckMate 275 into perspective. “Anti–PD-1 (programmed cell death protein 1) and anti–PD-L1 (programmed cell death ligand 1) agents represent a revolution in the...
Anti–PD-1 Contenders in Advanced Urothelial Cancer
Immunotherapy with anti–PD-1 (programmed cell death protein 1) and anti–PD-L1 (programmed cell death ligand 1) agents continues to advance in metastatic urothelial cancer, with positive showings in two clinical trials presented at the 2016 European Society for Medical Oncology (ESMO) Congress. The...
Expert Point of View: Florian Lordick, MD
Florian Lordick, MD, Professor of Oncology and Director of the University Cancer Center in Leipzig, Germany, offered some critical evaluation of the two studies. AGITG Phase II Trial For the AGITG’s phase II DOCTOR trial, he emphasized the need to show the impact on survival outcomes for...
Locally Advanced Esophageal Cancer Outcomes Improved With Neoadjuvant Therapy
In studies presented at the 2016 European Society for Surgical Oncology (ESMO) Congress, two different neoadjuvant treatment approaches improved the outcomes of patients with esophageal cancer. Investigators from the Australasian Gastro-Intestinal Trials Group (AGITG) reported that the addition of...
Numerous ESMO Presentations Focused on Anti–PD-1 Therapy in Lung Cancer and Melanoma
The 2016 European Society for Medical Oncology (ESMO) Congress was jam-packed with studies of the anti–programmed cell death protein 1 (PD-1) antibodies in non–small cell lung cancer and melanoma, where they have clearly changed the treatment paradigm. Here is a roundup of some of those trials,...
Clinical Strategies for Improving Endocrine Therapy in Metastatic Breast Cancer
Most women with hormone receptor–positive breast cancer receive endocrine therapy as part of their treatment, but “the reality is that patients who receive antihormone therapy in the metastatic disease setting ultimately develop disease progression, ” William J. Gradishar, MD, stated at the 18th...
Androgen Receptor Antagonists May Meet ‘Unmet Need’ in Triple-Negative Breast Cancer
Although there are no androgen receptor antagonists currently approved for the treatment of breast cancer, clinical trials indicate that these agents benefit some patients with triple-negative breast cancer, Tiffany A. Traina, MD, told participants at the 18th Annual Lynn Sage Breast Cancer...
Lack of Standardized Definitions of Cutaneous T-Cell Lymphomas Hampers the Collection of Reliable Data
Cutaneous T-cell lymphomas are a heterogeneous group of cancers. Some subtypes of cutaneous T-cell lymphomas are often misdiagnosed as benign skin diseases, making it challenging to gather reliable epidemiologic data. At the 3rd World Congress of Cutaneous Lymphomas (sponsored by the International...
Skin Cancer Foundation President Perry Robins, MD, Announces Retirement, Names Deborah S. Sarnoff, MD, His Successor
Perry Robins, MD, Founder and President of the Skin Cancer Foundation, was honored at the organization’s Champions for Change Gala, held October 18 at the Mandarin Oriental New York. Dr. Robins was honored at the event as a “Champion for Change” for his lifetime commitment to decreasing the...
Association of T-Cell CD62L Expression and Molecular Response to Tyrosine Kinase Inhibitor Therapy in Early Chronic-Phase CML
Higher baseline levels of T-cell expression of CD62L (L-selectin) were associated with a greater likelihood of molecular response to nilotinib (Tasigna) in early chronic-phase chronic myeloid leukemia (CML), according to a report by Sopper et al in the Journal of Clinical Oncology. The study...
Weight Loss May Help Prevent Multiple Myeloma
New research shows that excess weight increases the risk that a benign blood disorder will progress to multiple myeloma. The study, by a team at Washington University School of Medicine in St. Louis, is published in the Journal of the National Cancer Institute. Being overweight or obese has been...
Phase III Trial Shows Ado-Trastuzumab Emtansine Noninferior to Trastuzumab/Taxane in HER2-Positive Breast Cancer
In the phase III MARIANNE trial reported in the Journal of Clinical Oncology, Perez et al found that ado-trastuzumab emtansine (formerly known as T-DM1; Kadcyla) was associated with noninferior progression-free survival compared with trastuzumab (Herceptin) plus taxane in patients with...
Activation of WNT5A May Drive Glioblastoma Stem Cell Differentiation and Invasive Growth
Glioblastoma multiforme remains the most common and highly lethal brain cancer, known for its tendency to recur. Researchers at The University of Texas MD Anderson Cancer Center have identified a pathway by which cancer cells aggressively spread and grow in the brain, opening up new possibilities...
Johns Hopkins Awards Professorship to Melanoma Researcher
William H. Sharfman, MD, has been awarded the first Mary Jo Rogers Professorship in Cancer Immunology and Melanoma Research at Johns Hopkins University. Dr. Sharfman is Associate Professor of Oncology and Dermatology, Director of Cutaneous Oncology, Clinical Co-Director of the Johns Hopkins...
Encouraging First Study of Pembrolizumab in Cutaneous T-Cell Lymphoma
Immunotherapy with an anti–programmed cell death protein 1 (PD-1) inhibitor—pembrolizumab (Keytruda)—showed encouraging responses in patients with advanced cutaneous T-cell lymphoma (either mycosis fungoides or Sézary syndrome). Pembrolizumab achieved a 38% overall response rate and responses...
ASCO Answers Fact Sheets for Your Patients
Be sure to check out Cancer.Net’s updated ASCO Answers fact sheets on brain tumors; chronic lymphocytic leukemia; ovarian, fallopian tube, and peritoneal cancers; and oral and oropharyngeal cancers. These one-page (front and back) introductions include an overview of the disease, illustrations,...
ASCO Quality Improvement Grant Spotlight: The Ralph Lauren Center for Cancer Care
In 2016 and 2017, a team from The Ralph Lauren Center for Cancer Care (RLCCC) is participating in an ASCO Quality Improvement Grant program, which is supported by the Stavros Niarchos Foundation. The grant program aims to improve the delivery of cancer care in medically underserved communities by...
Plan Ahead for the Holidays With the Conquer Cancer Foundation
Share the message of hope, strength, and a world free from the fear of cancer with greeting cards and eCertificates from the Conquer Cancer Foundation (CCF). In appreciation of your gift, CCF will mail or ship greeting cards, or e-mail eCertificates. Cards and eCertificates feature artwork created ...
CancerLinQ™ Platform Hits Milestone of Having More Than 1 Million Patient Records in System
CancerLinQ LLC, a wholly owned nonprofit of ASCO, has announced that more than 1 million patient records are now in the CancerLinQ™ platform. In addition, 70 practices have signed agreements to participate in CancerLinQ™, representing more than 1,500 oncologists. “We are excited to reach this...
A Note of Thanks From the Conquer Cancer Foundation
Dear Friends: Each year, the Conquer Cancer Foundation of ASCO (CCF) Grants and Awards Ceremony is one of the highlights of the ASCO Annual Meeting. While most of the week in Chicago is packed with meetings, events, and presentations, the Grants and Awards Ceremony is a time for everyone to stop,...
Apply for ASCO Health Policy Fellowship to Improve Skills Needed to Shape Cancer Policy
ASCO is now accepting applications for its prestigious Health Policy Fellowship, a 1-year fellowship opportunity designed to give early-career oncologists the unique skills necessary to monitor and shape the regulatory and legislative policies that directly affect the practice environment and...
Research Highlights From the 2016 Palliative Care in Oncology Symposium
More than 650 attendees gathered in San Francisco on September 9 and 10 for the 2016 Palliative Care in Oncology Symposium, focusing on the theme of “Patient-Centered Care Across the Cancer Continuum.” Research presented during the Symposium demonstrated how integrating palliative care into cancer...
Cancer on the Global Stage: Incidence and Cancer-Related Mortality in Albania
The ASCO Post is pleased to present this special focus on the worldwide cancer burden. The aim of this special feature is to highlight the global cancer burden for various countries of the world. For the convenience of the reader, each issue will focus on one country from one of the six regions of ...
Christian U. Blank, MD, PhD, on Melanoma: Initial Data From the OpACIN Trial (German Language Version) 
Christian U. Blank, MD, PhD, of the Netherlands Cancer Institute, discusses in German study findings on neoadjuvant ipilimumab plus nivolumab in patients with palpable stage III melanoma. (Abstract LBA39)
Western Connecticut Health Network Names John A. Martignetti, MD, PhD, Network Director of the Laboratory for Translational Research
Western Connecticut Health Network (WCHN) has named physician-scientist John A. Martignetti, MD, PhD, Network Director of the Laboratory for Translational Research at the WCHN Biomedical Research Institute. Dr. Martignetti is Associate Professor of Genetics and Genomic Sciences, Oncological...
Prospective Cutaneous Lymphoma International Prognostic Index Initiative Moves Forward
A collaboration of international experts is tackling the challenges involved in understanding and managing the treatment of cutaneous lymphomas. The Prospective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study from the Cutaneous Lymphoma International Consortium brings together...
Adult Survivors of Childhood Cancers Report Long-Term Health Issues
Although progress in treatment and supportive care for children with cancer has resulted in improved survival of these patients, some survivors experience ongoing medical conditions from their cancer or its treatment, including poor general health, poor mental health, functional impairment,...
Expert Point of View: Youn Kim, MD
Commenting on this talk during the discussion afterward, Youn Kim, MD, of Stanford University School of Medicine, Stanford, California, said: “At our center, we use high-throughput sequencing of T-cell receptors daily in patients with cutaneous T-cell lymphomas, and it is a billable service paid...
Updated ASTRO Guideline Expands Pool of Suitable Candidates for Accelerated Partial-Breast Irradiation
On November 17, the American Society for Radiation Oncology (ASTRO) issued an updated clinical practice statement for accelerated partial-breast irradiation for early-stage breast cancer. The updated guideline reflects recent evidence that greater numbers of patients can benefit from accelerated...
High-Throughput Sequencing of T-Cell Receptors May Transform Diagnosis and Treatment of Cutaneous T-Cell Lymphomas
High-throughput sequencing of T-cell receptors may be a solution to some of the challenges confronting oncologists who treat cutaneous T-cell lymphomas. According to experts who presented talks on high-throughput sequencing of T-cell receptors at the 3rd World Congress of Cutaneous Lymphoma...
New Leadership Elected to American Society of Hematology
The American Society of Hematology (ASH) recently announced the election of four new members to its Executive Committee for terms beginning after the 2016 ASH Annual Meeting, December 3–6, in San Diego. Roy L. Silverstein, MD, will serve a 1-year term as Vice President followed by successive...
Novel Urine Test May Predict High-Risk Cervical Cancer
Johns Hopkins Medicine specialists reported they have developed a urine test for the likely emergence of cervical cancer that is highly accurate compared to other tests based on genetic markers derived directly from cervical tissue. The new urine test, they said, is different because it analyzes...
Cautious Optimism About Olaratumab in Soft-Tissue Sarcoma
The current plethora of drugs in development for oncology is leading to the testing of novel agents in common as well as rare diseases. Targeted therapies have been a focus of great interest in soft-tissue sarcomas, with testing of a variety of oral tyrosine kinase inhibitors leading to the...
Fulminant, Fatal Myocarditis Reported in Two Patients After Starting Combined Immune Checkpoint Blockade Treatment
In an article in The New England Journal of Medicine, Johnson et al reported the occurrence of fulminant, fatal immune-related myocarditis in two patients who received combined ipilimumab (Yervoy) and nivolumab (Opdivo) for metastatic melanoma. Patient Courses One patient was a 65-year-old woman...
Cabozantinib Shows Activity in Advanced RET-Rearranged NSCLC
In a phase II trial reported in The Lancet Oncology, Drilon et al found that cabozantinib (Cabometyx) produced responses in some patients with advanced RET-rearranged non–small cell lung cancer (NSCLC). RET rearrangements are found in 1% to 2% of NSCLCs. In the single-arm study, 25 evaluable ...
Expert Point of View: Alice T. Shaw, MD, PhD
Commenting on ASCEND-5, Alice T. Shaw, MD, PhD, Director of Thoracic Oncology at the Massachusetts General Hospital Cancer Center, Boston, noted that it is the first randomized study to examine how a second-generation anaplastic lymphoma kinase (ALK) inhibitor compares to standard second-line...
Studies Confirm Ceritinib’s Benefit in ALK-Positive Patients
For patients with advanced non–small cell lung cancer (NSCLC) harboring the ALK gene rearrangement, ceritinib (Zykadia) provided longer progression-free survival than chemotherapy in patients previously treated with chemotherapy and crizotinib (Xalkori), but gastrointestinal toxicity was...
